|
|
|||
|
|||
|
|
|||
|
antegren fda |
|||
|
|
|||
|
|||
![]()
|
|||
|
|
|||
|
antegren fda Biogen Idec and Elan Announce Intention to Submit for Approval for Multiple SclerosisBased on One-Year Data The decision to file a Biologics License Application (BLA) was made after discussionswith the FDA of one-year data from the two ongoing two-year Phase III trialsin MS antegren fda. The companies are committed to completing the two-year trials antegren fda. To protectthe integrity of the trials, the companies are not disclosing the one-year dataat this time. Biogen Idec and Elan are collaborating equally on the development of natalizumabfor MS, Crohn's disease, and rheumatoid arthritis. About the Antegren MS Clinical Trials About Antegren (natalizumab) |
|||
![]()
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| aantegren fda anntegren fda anttegren fda anteegren fda anteggren fda antegrren fda antegreen fda antegrenn fda antegren fda antegren ffda antegren fdda antegren fdaa ntegren fda ategren fda anegren fda antgren fda anteren fda antegen fda antegrn fda antegre fda antegrenfda antegren da antegren fa antegren fd a ntegren fda an tegren fda ant egren fda ante gren fda anteg ren fda antegr en fda antegre n fda antegren fda antegren fda antegren f da antegren fd a antegren fda nategren fda atnegren fda anetgren fda antgeren fda antergen fda antegern fda antegrne fda antegre nfda antegrenf da antegren dfa antegren fad aantegren fda theantegren fda antegren fda | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |